Kennedy Capital Management LLC Sells 28,586 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Kennedy Capital Management LLC decreased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 46.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,586 shares of the biopharmaceutical company’s stock after selling 28,586 shares during the quarter. Kennedy Capital Management LLC owned about 0.05% of Celldex Therapeutics worth $1,410,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CLDX. Vanguard Group Inc. grew its holdings in shares of Celldex Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,618,504 shares of the biopharmaceutical company’s stock valued at $72,061,000 after buying an additional 20,688 shares during the period. Panoramic Investment Advisors LLC bought a new stake in shares of Celldex Therapeutics in the fourth quarter worth about $258,000. Arizona State Retirement System raised its position in shares of Celldex Therapeutics by 20.3% during the fourth quarter. Arizona State Retirement System now owns 13,758 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 2,322 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of Celldex Therapeutics during the 4th quarter valued at about $994,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Celldex Therapeutics by 3.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock valued at $1,041,000 after purchasing an additional 962 shares during the period.

Insiders Place Their Bets

In other news, CFO Samuel Bates Martin sold 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the sale, the chief financial officer now directly owns 25,128 shares of the company’s stock, valued at $855,608.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 35,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $34.05, for a total transaction of $1,191,750.00. Following the completion of the sale, the chief financial officer now owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Elizabeth Crowley sold 38,597 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the completion of the transaction, the vice president now owns 9,074 shares in the company, valued at $305,249.36. The disclosure for this sale can be found here. Insiders have sold a total of 266,332 shares of company stock valued at $9,155,821 over the last 90 days. 3.80% of the stock is currently owned by insiders.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $38.11 on Thursday. The stock has a 50 day moving average price of $36.76 and a 200 day moving average price of $39.16. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. As a group, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.39 earnings per share for the current year.

Wall Street Analyst Weigh In

CLDX has been the subject of several research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday. Wolfe Research assumed coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday. Finally, Stifel Nicolaus began coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.17.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.